RECOVER/ARVIN-GOODS
Arvin Goods, the Seattle-based responsible apparel brand, has announced the release of its latest sock collection, crafted from Recover™ recycled cotton fiber. Since launching in 2019, the company has been at the forefront of sustainable fashion and is one of the few brands in the market utilizing recycled materials for its entire collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215745837/en/
(Photo: Arvin Goods)
The latest launch features crew socks made from 79% recycled materials, including 43% recycled polyester and 36% Recover recycled cotton fiber. Recover’s proprietary recycled fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel supply chain. Manufacturing just one pair of Arvin Goods socks made with 36% Recover fiber saves up to 18 gallons of water compared to a pair made with conventional cotton.
Boris Mercier, SVP Marketing at Recover, said, “Our ongoing work with Arvin Goods was born out of a shared belief in the importance of circular fashion that never sacrifices quality, feel, or style. As the ingredient brand of reference in recycled cotton, we aim to educate consumers to make more conscious choices and accelerate the adoption of sustainable initiatives within the casual wear segment.”
For each pair of socks, responsibility is the core of Arvin’s approach to the design, manufacturing, and distribution. As well as using low-impact impact recycled materials, responsibility was also prioritized in the value chain. Thanks to Recover’s strategic partnership with Ferre Yarns, based locally in Alicante, Spain the impact of transportation was also minimized.
Dustin Winegardner, Managing Partner at Arvin Goods, commented, “We have been working with Recover™, and the Ferre family of yarns since the beginning of Arvin Goods. Making it official like this and stamping the R on our packaging is an exciting step for our brand. Being able to source materials in Spain, and manufacture nearby in Portugal moves us further in our mission to deliver The Cleanest Basics on the Planet.”
Paqui Ferre, Sales and Marketing Director at Ferre, also commented, “Ferre has been working with Arvin Goods since the beginning of its history. In a clear commitment to sustainability, Arvin makes products using our most iconic yarn, FBlue. Consistent with our brand vision, FBLUE 100% recycled yarns deliver the perfect combination of circularity, performance, and color accuracy. A blend with Recover recycled cotton that answers the global call for sustainably sourced yarns while providing inspiring colors for Arvin Goods products.”
The new collection not only exemplifies Arvin Goods' sustainable ethos but also provides customers with a stylish and comfortable choice for everyday wear. The brand continues to set a new standard for low-impact fashion, encouraging consumers to make conscious choices that positively impact the planet.
The Arvin Goods recycled fiber collection starts at $12 USD and is available to purchase through their website.
Find out more about the collaboration here.
About Arvin Goods
Established in 2019 Arvin Goods has set out to help clean up a dirty industry. By utilizing recycled base materials and minimizing the movement of materials in manufacturing they are reducing the impact of one of the world's most consumed categories. Basics.
Arvin Goods produces comfortable on-trend products, that also happen to be the lowest-impact socks in the marketplace. Arvin Goods is based in Seattle, Washington USA.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Ferre
Ferre is a fourth-generation family business with a history of more than 75 years innovating the manufacture of high-quality recycled yarns. Our open-end spin factory is based in Banyeres de Mariola (Alicante), Spain and the company, founded in 1947, has been innovating the cotton recycled spinning process ever since.
We work every day to improve our products and help our customers to maximize the full potential of our low-impact yarns, always guided for the commitment of making more with less. Ferre yarns stand out for their quality and low-impact products, bringing accurate and beautiful colours to the sustainable fashion value chain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215745837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
